Abstract
Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases. Its actions, once thought to be limited to the distal convoluted tubule of the kidney, are now recognised to be wide-ranging, including interactions with mineralocorticoid receptors in diverse cardiovascular sites to mediate vascular and myocardial remodelling and dysfunction. The latter are referred as non-epithelial actions.
Spironolactone, an aldosterone receptor antagonist, is indicated for the treatment of mineralocorticoid hypertension, but its use is limited by an adverse effect profile that includes not only by hyperkalaemia, but also antiandrogenic and progestational effects resulting from its poor specificity for the aldosterone receptor. Eplerenone is the first selective aldosterone receptor antagonist to be developed and recently gained approval from the US FDA for treatment of systemic hypertension. This was based on studies which demonstrated that eplerenone had a blood pressure-lowering profile that was equivalent to existing antihypertensive agents, was useful for treatment of low-renin and systolic hypertension, maintained utility even as add-on therapy to other antihypertensive agents, and exerted beneficial effects on hypertension-related left ventricular hypertrophy and renal impairment. Perhaps most notably, eplerenone was generally well tolerated, and did not cause the antiandrogenic and progestational adverse effects commonly observed with spironolactone.
Similar content being viewed by others
References
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–17
Simpson SA, Tait JF, Wettsein A, et al. Konstitution des aldosterons, des neuen mineralocorticoids. Experientia 1954; 10: 132–3
Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002; 62: 723–31
Pratt JH. Low-renin hypertension: more common than we think? Cardiol Rev 2000; 8: 202–6
Lombes M, Alfaidy N, Eugene E, et al. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175–82
Brilla CG, Rupp H, Funck R, et al. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J 1995; 16 Suppl. O: 107–9
Takeda Y, Miyamori I, Inaba S, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997; 29: 45–8
Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849–65
Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269: E657–62
Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26: 971–8
Roland BL, Krozowski ZS, Funder JW. Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies. Moll Cell Endocrinol 1995; 111: Rl–7
Gomez-Sanchez EP, Fort CM, Gomez-Sanchez CE. Intracer-ebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol 1990; 258: E482–4
Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344: 431–42
Klassen PS, Svetkey LP. Diagnosis and management of renovascular hypertension. Cardiol Rev 2000; 8: 17–29
Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063–8
Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353: 1341–7
Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol 2001; 28: 783–91
Moneva MH, Gomez-Sanchez CE. Pathophysiology of adrenal hypertension. Semin Nephrol 2002; 22: 44–53
Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441–9
Schunkert H, Hense HW, Muscholl M, et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997; 77: 24–31
Schlaich MP, Schobel HP, Hilgers K, et al. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000; 85: 1199–206
Fagard RH, Lijnen PJ, Petrov VV. Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. J Hum Hypertens 1998; 12: 195–202
Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem 1998; 273: 4883–91
Hatakeyama H, Miyamori I, Takeda Y, et al. The expression of steroidogenic enzyme genes in human vascular cells. Biochem Mol Biol Int 1996; 40: 639–45
Takeda Y, Miyamori I, Yoneda T, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996; 81: 2797–800
Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000; 57: 1408–11
Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709–16
Burgess E, Niegowksa J, Tan KW, et al. Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension [abstract]. Am J Hypertens 2002; 15 Suppl. I: 23A
Weinberger M, MacDonald T, Conlin PR, et al. Comparison of eplerenone and losartan in patients with low-renin hypertension [abstract]. Am J Hypertens 2002; 15 Suppl. I: 24A
Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148–55
White WB, Lewin AJ, Nestel P, et al. Comparison of selective aldosterone blockade versus calcium antagonism on blood pressure, vascular compliance, and microalbuminauria in systolic hypertension in older people [abstract]. Am J Hypertens 2002; 15 Suppl. I: 23A
Pitt B, Reichek N, Metscher B, et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. Am J Hypertens 2002; 15 Suppl. I: 23A
Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens 2002; 15 Suppl. I: 24a
Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117–23
Van Mieghem W, von Behren V, Balazovjech I, et al. Eplerenone is safe and effective as add-on therapy in hypertensives patients uncontrolled with calcium channel blockers or beta blockers [abstract]. Eur Heart J 2002; 23 Suppl.: 211
Prisant LM, Kram H, Roniker B, et al. Endocrine relationships of co-administration of eplerenone with an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker in hypertensive patients [abstract]. J Clin Pharmacol 2001; 41 Suppl. 1: 1029A
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21
Acknowledgements
Danny Liew is supported by a Postgraduate Medical Scholarship from the National Health and Medical Research Council of Australia. Henry Krum has received study support from Pharmacia Corporation for studies on eplerenone.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liew, D., Krum, H. Aldosterone Receptor Antagonists for Hypertension. Drugs 63, 1963–1972 (2003). https://doi.org/10.2165/00003495-200363190-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200363190-00001